Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA to Exchange Personnel with Universities, Research Institutes in the Field of Cutting Edge Technologies
April 9, 2012
- MHLW Urges Generic Drug Makers to Ensure Availability of Products for All Indications Approved for Original Drugs
April 6, 2012
- MHLW to Issue 80 Requests for Development of Unapproved Drugs/Indications This Week
April 5, 2012
- Japan to Maintain Drug Pricing System in TPP Talks: Health Minister Komiyama
April 4, 2012
- MHLW Presents Standard Time Frames for Drug Approval Process by Individual Procedure
April 3, 2012
- PMDA Strengthens Consultation System to Support Biomarker Development
April 3, 2012
- MHLW Prepares Q&A to Address Healthcare Professionals’ Concerns About Generic Drugs
April 3, 2012
- DPJ’s PAL Subcommittee to Hold Off Final Recommendation on PAL Amendment Until Late April
April 2, 2012
- MHLW Approves 10 Products Including Pfizer Japan’s Xalkori
April 2, 2012
- CSIMC Recommends Approval of Insurance Coverage for Diagnosis for Xalkori Administration
March 30, 2012
- MHLW Proposes Pricing of Long-Listed Products to Be Concluded in FY2013: CSIMC Meeting
March 30, 2012
- CSIMC to Discuss Introduction of Medicoeconomic Assessment in FY2014
March 30, 2012
- MHLW Issues Safety Warning on Use of Afinitor in HBV Carriers
March 30, 2012
- Office of Medical Innovation Begins Discussions on “Five-year Strategy for Medical Innovation”, Compiles Interim Report by Mid-April
March 29, 2012
- “MHLW Ideal” Placement for Drug Discovery Support Organization: Medical Innovation Office Counselor Hachiyama
March 28, 2012
- Handling of Adverse Reaction Data an Issue in Access System Adaptation: MHLW Deputy Director Miyata
March 28, 2012
- Eight Products/Indications Including Xalkori to Receive Formal Approval by End of Month
March 28, 2012
- Use of Medicoeconomic Assessment in Drug Pricing “Unrealistic”: DG for Policy Planning and Evaluation Katori
March 28, 2012
- MHLW Study Group Decides on Next 5-Year Plan for Activation of Clinical Research
March 27, 2012
- Council for Improvement of the Distribution of Ethical Drugs Agrees to Establish Working Team, Focus on Spreading “Mutual Understanding”
March 27, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…